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Summary
Organic small molecules generally act by perturbing
the function of one or more cellular target proteins,
the identification of which is essential to an under-
standing of the molecular basis of drug action. Here
we describe the application of methotrexate-linked
small molecule ligands to a mammalian three-hybrid
interaction trap for proteome-wide identification of
small molecule targets, quantification of the targeting
potency of unmodified small molecules for such
targets in intact cells, and screening for inhibitors of
smallmolecule-protein interactions.During the course
of this study we also identified the pyrido[2,3-d]pyrim-
idine PD173955, a known SRC kinase inhibitor, as a
potent inhibitor of several ephrin receptor tyrosine
kinases. This finding could perhaps be exploited in
the design of inhibitors for this kinase subfamily,
members of which have been implicated in the patho-
genesis of various diseases, including cancer.
Introduction
Mechanism of action studies play an important role in
understanding the biological activity profiles of small
molecules, in evaluating their potential as chemical
genetics tools to study protein functions, and in the dis-
covery and/or characterization of drug candidates and
their therapeutic potential. Recent chemical proteomics
studies have revealed that small molecules, including
marketed drugs and drug candidates, are often less
selective than previously recognized [1–6]. Even struc-
turally highly related molecules may have significantly
distinct target profiles, underscoring the general diffi-
culty in predicting the composite target profile of a small
molecule and, consequently, the importance of pro-
teome-wide approaches in elucidating the mechanism
of action of organic small molecules.
*Correspondence: nikolai.kley@gpc-biotech.com
3 Lab address: http://www.gpc-biotech.comVarious chemical proteomic methods for the identifi-
cation of small molecule-protein interactions have been
described in recent years. These include affinity chro-
matography-based methods, activity-based proteome
profiling (ABPP), phage display, protein arrays, and
yeast three-hybrid (Y3H) [1–4, 7–10]. Y3H is an extension
of yeast two-hybrid (Y2H), which was developed by
Fields and Song [11]. In Y2H, the interaction of two pro-
teins is detected by linking their association to the tran-
scriptional activation of a reporter gene. In Y3H, protein
complex formation is mediated by a small molecule
hybrid ligand [3, 12, 13]. Methotrexate (MTX) hybrid
ligands have been shown to successfully display small
molecules in Y3H, thereby enabling the identification
of candidate cellular targets that these molecules bind
to [13–15]. An attractive feature of Y3H is that it can be
automated at various steps and used to perform large-
scale screens of proteome cDNA libraries, specific pro-
tein classes, or mutants of the same protein [3]. Target
fingerprints identified in this manner can lead to new
insights into structure-activity relationships (SARs) of
small molecules. In addition, they can identify a drug-
resistant variant(s) of a target protein, which could be
used to explore its role in mediating a pharmacological
effect of interest, or mutations in a target protein that
might emerge in drug-resistant variants during therapy
[16, 17]. As with all technologies, however, Y3H is sub-
ject to certain limitations [3]. For instance, it is limited
to the detection of interactions with proteins or protein
domains that effectively translocate into the nucleus.
One drawback of using yeast cells as a host for a
three-hybrid system is that these cells are generally not
very permeable to nonhybrid small molecules. This pre-
vents the use of Y3H in determining the ability of com-
pounds to interfere with or actively reverse a specific
hybrid ligand-target protein interaction and, hence, its
use in ranking compounds with respect to their target-
ing potencies, as well as random screening for small
molecule-protein interaction modifiers. Competitive
screening assays would most ideally be performed in
mammalian cells.
Here we describe the development of a mammalian
three-hybrid system (M3H) that complements Y3H while
circumventing some of its limitations. In an analogous
strategy to that used in the Y3H system, we adapted
a two-hybrid protein-protein interaction trap, MAPPIT
[18, 19] (mammalian protein-protein interaction trap),
to be used with methotrexate-based chemical dimer-
izers. MAPPIT is a complementation system in which
the interaction of two fusion proteins (‘‘bait’’ and ‘‘prey’’
proteins) restores ligand-dependent activation of JAK/
STAT signaling to a signaling-deficient cytokine recep-
tor (see Figure 1). Various types of protein-protein
interactions have been detected with MAPPIT and
reverse-MAPPIT [18, 20–23]. An important application
of MAPPIT is in the de novo identification of protein-
protein interactions using cDNA library screening, and
this suggests that it might also prove applicable to the
design of an M3H system for use in target identifica-
tion. Another attractive feature of MAPPIT is that protein
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712Figure 1. The MASPIT System
(A) The JAK-STAT signal transduction system. Phosphorylation of the cytokine receptor by activated JAK provides a STAT docking site.
Recruited STAT is subsequently phosphorylated by JAK, leading to its activation.
(B) The MAPPIT system. Here the cytokine receptor is a chimera, including the ligand binding domain of the Epo receptor (EpoR) and the
cytoplasmic domain of a mutated leptin receptor (LRF3), which lacks functional STAT3 recruitment sites. Complementation and restoration
of JAK2/STAT3 signaling is achieved by interaction of a bait protein fused to the receptor and a prey protein fused to the C-terminal portion
of gp130, which contains four STAT3 binding sites.
(C) The MASPIT system. eDHFR is fused to the chimeric receptor, enabling the display of an MTX hybrid ligand in which a small molecule
is linked to MTX via a polyethylene glycol repeat (n = 5) linker/spacer. Interaction of this small molecule with a prey-gp130 protein leads to
recruitment of a docking site for STAT3, which now can be phosphorylated by JAK2. Activation of JAK2 is triggered by binding of Epo
to the extracellular domain of the chimeric receptor. Collectively, a productive small molecule-protein interaction in MASPIT restores an
Epo-dependent activation of JAK2/STAT3 signaling and induction of the expression of a STAT3-responsive reporter gene.interactions occur in the cytoplasm; therefore, no nu-
clear translocation of fusion proteins or small molecules
would be required in a 3H version of it. Furthermore,
interaction-triggered signal transmission is highly ligand
regulated, which we reasoned could be of significant
benefit in developing a robust M3H proteome cDNA
library screening method with acceptable signal/noise
ratios. Here we describe such a mammalian small
molecule protein interaction trap (MASPIT) and its suc-
cessful application to small molecule target identifica-
tion and activity profiling of organic small molecules in
intact cells.
Results
The MASPIT System
Figure 1 describes features of cytokine receptor-associ-
ated JAK/STAT signaling, the basic components of
the MAPPIT system, as described previously [18], and
the MASPIT system as developed in this study. As in the
Y3H system we described earlier [3, 13], the MASPIT
system used here employs an Escherichia coli DHFR
(eDHFR) fusion protein for the display of a methotrexate
fusion compound (MFC) in which a small molecule is
connected to MTX via a polyethylene glycol (PEG) repeat
linker/spacer. As outlined in Figure 1, a small molecule-
protein interaction is detected as an erythropoietin
(Epo)/MFC-dependent activation of JAK/STAT3 signal-
ing, which can be monitored by measuring the activity
of a reporter gene (e.g., luciferase) that is under the
control of a STAT3-responsive rat pancreatitis-associ-
ated protein 1 (rPAP1) promoter. HEK293 or HEK293T
(the latter express SV40 large T antigen) were used as
host cells.Use of MTX Hybrid Ligands Derived from Diverse
Small Molecule Chemotypes
Figure 2 summarizes MASPIT interaction results for
various types of small molecules and their known target
proteins when these were transiently expressed in
HEK293T cells. These compounds are as follows:
1. AP1867, which is an FK506 analog that specifically
binds with high affinity a mutated form of FKBP12
(FKBP12F36V) [24].
2. PD173955, which is a potent ABL kinase inhibitor
[25, 26].
3. RGB-285961 and RGB-286147, which are potent
inhibitors of CDK2. These compounds belong
to a class of 1,3,6-trisubstituted-pyrazolopyrimi-
dones [27]. We have recently shown that MFC
derivatives of these compounds interact with
CDK2 in Y3H [15].
4. RGB-285978, which is a potent inhibitor of cyclin-
dependent kinases (CDKs) and GSK3. RGB-
285978 belongs to the chemical class of indeno-
pyrazoles [28, 29]. We have previously shown
that a related member of this class (IP1) interacts
with CDKs and GSK3 in Y3H [13].
5. E7070, which is an inhibitor of carbonic anhydrase
(CAII) [30].
These small molecules were each coupled to MTX.
The chemical structures of their MFC derivatives are
shown in Figure 2A. MTX coupled to a small molecule
was observed to retain high affinity for purified eDHFR,
indicating that the PEG linker was attached to a suitable
position onMTX (KD in the picomolar tonanomolar range,
as determined in BIACORE assays; data not shown).
Given that MTX exhibits variable antiproliferative effects
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(A) Small molecules and MFC derivatives used in this study.
(B) Effects of MFCs on HEK293T cell proliferation/viability (IC50s were determined following 24 hr exposure to the MFC with the SRB assay or
the Cell TiterGlo ATP luminescence assay) and induction of a STAT3-responsive luciferase reporter. For MASPIT studies, HEK293T cells were
transiently transfected with the EpoR-LepRF3-DHFR bait, the rPAP-luciferase reporter, and the indicated gp130-target fusion vectors. The
transfected cells were exposed to Epo in the presence or absence of the MFC. The MFC-dependent induction of the luciferase reporter is
shown. The concentrations of MFCs used in this study were RGB-286649 at 0.01 mM, RGB-286617 and RGB-286711 at 0.1 mM, RGB-
286156 at 0.2 mM, RGB-286580 at 0.3 mM, and RGB-286298 at 1 mM.in mammalian cells (GI50s range across the National
Cancer Institute tumor cell panel, 0.3 to >30 mM; see
http://www.dtp.nci.nih.gov/), we evaluated the effects
of MTX and MFCs on HEK293T cell growth and viability.
Neither MTX nor any of the MFCs exhibited antiprolifera-
tive or cytotoxic activities that would seemingly prevent
their use in MASPIT (IC50s > 3 mM at 24 hr incubation; see
Figure 2B). Indeed, as summarized in Figure 2B, by 24 hr
incubation, all MFCs induced a strong Epo-dependent
expression of a STAT3-responsive luciferase reporter
gene in HEK293T cells expressing the appropriate target
protein (even at MFC concentrations well below their cell
proliferation IC50s; see also Figure 3).
As shown in Figure 3, MFC-induced reporter expres-
sion was dependent on (1) ligand/Epo activation of the
chimeric EpoR-LepRF3-DHFR receptor, (2) MFC con-
centration, and (3) level of expression of the small-
molecule target-gp130 fusion protein. For instance, in
cells expressing FKBP12F36V, the AP1867-MFC (RGB-
286617) caused a dose-dependent induction of lucifer-
ase expression, which is dependent on the presence
of Epo (Figure 3A). Similarly, MFCs for the ABL kinase
inhibitor PD173955 (RGB-286649) and the CDK2 in-
hibitor RGB-285961 (RGB-286156) induced luciferaseexpression in a dose-dependent fashion (Figures 3B
and 3C, respectively). As with RGB-286156 (Figure 3C),
reporter activation was also time dependent (high levels
of induction were observed for all MFCs within 24 hr;
Figure 2B) and proportional to the level of expression
of the gp130-prey fusion protein (CDK2 in this example).
Similar results were obtained for other small molecule
chemotypes, as illustrated by the dose-dependent in-
duction of luciferase expression with RGB-286711
(Figure 3D), the MFC for the CAII inhibitor E7070. Collec-
tively, the results described in Figures 2 and 3 indicate
that MASPIT exhibits a broad dynamic range and that
it accommodates small molecules that exhibit very dif-
ferent biological activities (targets and binding modes).
Proteome Screening and De Novo Identification
of Small Molecule Protein Targets
Having established that MASPIT can be used to detect
pairwise interactions of small molecules with their target
proteins, we explored next its application to proteome
scanning. For this purpose, we used genetically engi-
neered HEK293 cells that stably express the EpoR-
LepRF3-DHFR fusion protein and carry an integrated
STAT3-responsive rPAP1-IL5 receptor (IL5R) reporter
Chemistry & Biology
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(A) Dependence of MASPIT signaling on Epo and MFC. HEK293T cells were transiently transfected with vectors encoding the EpoR-LepRF3-
DHFR bait, the rPAP1-luciferase reporter, and gp130-FKBP12F36V, and a vector encoding b-galactosidase (for transfection efficiency normal-
ization). Transfected cells were exposed to MFC at concentrations of 0.01 and 0.1 mM in the presence or absence of Epo for 24 hr. Normalized,
MFC-dependent induction of the luciferase activity is shown.
(B–D) Dependence of MASPIT signaling on MFC concentration (B–D; 24 hr MFC exposure), time of MFC exposure (C, middle panel; RGB-
286156 at 0.3 mM), and gp130-target expression levels (C, lower panel; RGB-286156 at 0.3 mM, 24 hr). HEK293T cells were transiently trans-
fected as described above, but including the indicated gp130-target fusion vectors. The transfected cells were exposed to Epo in the presence
or absence of the MFC, and MFC-dependent induction of the luciferase expression was determined.gene [22]. The IL5R reporter used here lacked the cyto-
plasmic domain of the receptor; this avoids competition
for JAK binding and removes potential receptor internal-
ization motifs. Expression of this IL5R was monitored by
flow cytometry using an anti-IL5R-specific monoclonal
antibody. These recombinant HEK293 cells were also
engineered to express a murine ecotropic virus receptor
for viral infection applications. A representative experi-
ment in which the integrated rPAP1-IL5R reporter is
activated in response to interaction of ABL with the MFC
of the ABL inhibitor PD173955 [25, 26, 31], RGB-286649,
is shown in Figure 4A. Treatment of ABL-gp130-
expressing cells with Epo and RGB-286649 was found
to promote a strong activation of IL5R reporter expres-
sion in approximately 25% of the cells. In this particular
experiment, the efficiency of infection with the ABL-
expressing virus was approximately 25%, suggesting
nearly quantitative activation of the reporter in infectedcells. Similar results were observed for other pairwise
interactions (data not shown). These experiments estab-
lished that viral transduction and integrated expression
of a gp130-target fusion protein can lead to a robust
activation of the integrated STAT3-responsive IL5R
reporter gene in these cells.
Next, we explored the use of MASPIT in cDNA library
screening and in the de novo identification of small
molecule target proteins. A cDNA library was con-
structed from HEK293 mRNA in a retroviral vector (this
library contained >1 3 108 primary clones, >99% of
which contained inserts). The IL5R reporter cells were
infected with the retroviral library and subjected to
various cycles of enrichment for MFC-dependent IL5R-
positive cells (see Experimental Procedures), followed
by flow cytometric single-cell sorting into 96-well micro-
titer plates (Figure 4B). Individual cell populations were
subsequently screened for MFC- and Epo-dependent
Mammalian Three-Hybrid System
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(A) Induction of MASPIT signaling with integrated system components. The cell line T-Rex44-eDHFR-gp130-ABL, which carries integrated
copies of transgenes encoding the EpoR-LepRF3-DHFR fusion protein, gp130-ABL target protein, and an IL5R reporter, was exposed to
the RGB-286649 (0.30 mM) MFC in the presence of Epo for 24 hr or left untreated. Cells were stained with an anti-IL5R antibody and positive
cells were quantified by flow cytometry.
(B) MASPIT cDNA library screening workflow.
(C) Kinases identified in a proteome library screen with the MFC RGB-286649.reporter activation by fluorescence activated cell sorting
(FACS).
Figure 4C shows the results of a cDNA library screen
we performed with RGB-286649, the MFC incorporating
the ABL tyrosine kinase inhibitor PD173955 (see Figure 2
for compound details). In this screen, we identified a
number of different tyrosine kinases as well as one Ser/
Thr kinase. Only kinases were identified in this screen.
PD173955 is a member of the pyrido[2,3-d]pyrimidine
chemical class. Compounds of this class were initially
developed as broadly active inhibitors of several tyro-
sine kinases, including SRC-like kinases and fibroblast
growth factor receptors (FGFRs) [25, 26, 31, 32]. Here
we identified the SRC kinases LYN and FYN, as well as
FGFR1, as targets of PD173955 in MASPIT. We also
identified several additional kinases that, to our knowl-
edge, had not previously been reported as targets of this
compound—such as various ephrin receptors (Eph re-
ceptor tyrosine kinases) and cyclin G-associated kinase
(GAK). PD173955 was found to potently inhibit the
in vitro kinase activity of these enzymes (Figure 4C;
GAK was not evaluated). These findings validate the
MASPIT results and further support the conjecture that
this compound is less selective than previously known.
Interaction of the MFC for PD173955 with specific ephrin
receptors was also observed with Y3H in a directed array
analysis using yeast cells expressing these target pro-
teins (data not shown). These were, however, not identi-fied in a Y3H cDNA library screen, although this em-
ployed a HeLa cell cDNA library rather than HEK293
cDNA library (data not shown). Future comparative
studies might shed more light onto potential differences
in target profiles that may be obtained with one or the
other screening method, although such differences are
likely to vary from case to case due to the multiple vari-
ables that generally govern cDNA library screening re-
sults. Some of the targets identified in the MASPIT screen
(including GAK), albeit not all (e.g., EphA2, B1, and B2),
were recently also identified and validated for a molecule
highly related to PD173955, using a biochemical ap-
proach to small molecule target identification [33].
Competition Assays and Determination
of Small Molecule Targeting Potencies
If stimulation of reporter gene activation and expression
by a hybrid ligand is mediated by crosslinking of DHFR
and target fusion proteins, then the individual compo-
nents of that ligand (i.e., MTX and the small molecule
of interest) should act as competitive inhibitors of
reporter expression. Competition assays should pro-
vide (1) a means to directly validate a candidate small
molecule-protein interaction (e.g., such as identified
in a cDNA library screen) and (2) an opportunity to com-
pare and rank small molecules on the basis of their rela-
tive ability to displace a hybrid ligand from its target pro-
tein(s) in intact cells. Such cellular targeting potency is
Chemistry & Biology
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HEK293T cells were transiently cotransfected with the standard components (EpoR-LepRF3-DHFR bait, the rPAP-luciferase reporter, and the
b-galactosidase control vector) and the indicated gp130-target vectors. Transfected cells were exposed for 24 hr to Epo and the indicated
MFC in the presence or absence of a competing small molecule. The normalized luciferase activity as a function of the fully induced control
(i.e., MFC and Epo) is presented.
(A) MTX competes with RGB-286649 (0.01 mM) for binding to DHFR.
(B) PD-173955 and imatinib compete with RGB-286649 (0.01 mM) for binding to ABL.
(C) The small molecule CDK inhibitor, RGB-285961, competes with RGB-286156 (0.2 mM) for binding to CDK2.
(D) Small molecule CAII inhibitors, E7070 and methazolamide, compete with RGB-286711 (0.1 mM) for binding to CAII.expressed as an EC50 value, the compound concentra-
tion giving half-maximal inhibition of reporter expres-
sion that is observed in response to an MFC (competi-
tion is performed within the linear/dynamic range of
the assay as relates to the MFC; see, for example, Fig-
ure 3). Below we summarize results of various competi-
tion experiments.
Figure 5A shows that MTX inhibits RGB-286649 (MFC
of the ABL inhibitor PD173955)-induced reporter ex-
pression in a dose-dependent fashion, with an EC50
value ofw1 nM. This value is significantly below the con-
centration at which antiproliferative effects of MTX were
apparent (see Figure 2; IC50 is > 3 mM at 24 hr incuba-
tion), suggesting that inhibition of reporter expression
was due to binding of MTX to the DHFR fusion protein
and not to an unspecific loss in cell viability. An EC50
value of w1 nM also suggests that MTX retains a high
relative affinity for the DHFR fusion protein in these cells.
Figures 5B–5D outline competition experiments with
kinase and carbonic anhydrase small molecule inhibi-
tors. A dose-dependent inhibition of MFC-induced
luciferase reporter expression was observed for these
competitor molecules, with EC50 values in the range of
28–80 nM. It should be noted that in a situation where
the target protein is present in excess, an EC50 value
might underestimate the cellular potency of a competi-
tor. This is because it would underestimate the compo-
nent of its value that reflects binding affinity (i.e., binding
could be stronger than would appear from the assay).
Thus, for the experiments shown in Figure 5, we triedto achieve assay conditions in which the target protein
was not in excess (these conditions are generally easily
achieved; see Figure 3C). Figure 6A shows control
experiments that further demonstrate in two ways that
inhibition of MASPIT signaling reflects inhibition of
MFC-target protein interaction by the competitive com-
pounds. First, antiproliferative effects were apparent
only at much higher concentrations (IC50s > 3 mM, 24 hr
incubation), arguing against a nonspecific effect related
to changes in cell viability. Second, compounds did not
inhibit leukemia inhibitory factor (LIF)-induced JAK/
STAT3 signaling. LIF induces JAK/STAT3 signaling via
endogenous gp130 in HEK293 cells. Accordingly, at
the tested concentration of 100 nM (which exceeds any
of the EC50 values), the competitor compounds did not
significantly inhibit LIF-induced STAT3 phosphorylation.
In contrast, a known inhibitor of JAK/STAT signaling,
cucurbitacin [34, 35], significantly inhibited LIF-induced
STAT3 phosphorylation (99.3% inhibition at 5 mM).
Importantly, competitor compounds (100 nM) also did
not inhibit LIF-induced expression of a stably integrated
STAT3-responsive IL5R reporter gene in HEK293 cells.
Individual EC50 values are summarized in Figure 6B.
For comparison, compound IC50 values for in vitro
inhibition of enzymatic activities of purified proteins
are also shown. A wide spread in EC50/IC50 ratios was
observed for the different compounds. If one assumes
that binding efficiency generally correlates well with
potency of enzyme inhibition (for example, see study
by Fabian et al. [4]), these results would suggest that
Mammalian Three-Hybrid System
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(A) Compounds used in competition experiments (Figure 5) are not cytotoxic to HEK293T cells (24 hr exposure, SRB assay), and do not inhibit
LIF-induced phosphorylation of STAT3 (HEK293T cells) or STAT3-dependent induction of IL5R expression in HEK293 cells (T-Rex-44). The
phosphorylation of STAT3 and expression of IL5R was measured following 15 min and 16 hr of exposure, respectively, to LIF in the presence
or absence of a particular small molecule (cucurbitacin at 5 mM, all other compounds at 0.1 mM).
(B) Comparison of MASPIT EC50 values with IC50 values for in vitro enzyme inhibition. IC50 for methazolamide was taken from Abbate et al. [30].
The IC50 value for imatinib is in the range of previously reported values [40].
(C) Inhibition of cellular CrkL phosphorylation by imatinib. KU-812 leukemia cells, which express BCR-ABL, were either left untreated or ex-
posed to a dose range of imatinib for 24 hr. The percentage of cells expressing phosphorylated CrkL was determined by flow cytometry. nd,
not determined.some compounds were qualitatively more effective than
others in targeting their receptors in a cellular environ-
ment (e.g., see results for imatinib versus PD13955). Cel-
lular targeting efficiency may depend on numerous fac-
tors, including cell permeability, conformation of the
target protein, relative abundance of a target protein
compared to other target proteins, and cellular con-
stituents that may affect protein binding. Given that a
MASPIT EC50 value is likely to integrate many such vari-
ables, it could provide a novel means to evaluate the
intracellular targeting efficiency of a small molecule
(and compare it to others). This supposition is further
supported by the results obtained with the ABL inhibi-
tors PD173955 and imatinib, which show that an EC50
value for a specific target protein (ABL in this case)
can correlate well with the cellular activity of a com-
pound that is mediated by such a target. Accordingly,
imatinib was found to exhibit an EC50 value for ABL
(70 nM) which correlated well with its IC50 for inhibition
of BCR-ABL-driven phosphorylation of CrkL in KU812leukemia cells (180 nM; Figure 6C) and IC50 for inhibition
of BCR-ABL-dependent KU812 cell viability (137 nM).
The EC50 for PD173955 (28 nM) was also similar to its
IC50 for inhibition of KU812 cell viability (16 nM).
Rapid Kinetics Competition Assays
As described above, high levels of transcriptional induc-
tion and expression of a STAT3-responsive reporter
might require exposure of cells to an MFC for up to
24 hr. A more rapid readout of an interaction might be
preferable for competition assays, in particular for com-
pounds that might exhibit cytotoxic activities or inhibit
STAT3-induced reporter expression indirectly (i.e.,
by a mechanism other than direct inhibition of MFC-
target interaction). In Figure 6, we describe the use of
a STAT3 phosphorylation assay to monitor LIF-induced
activation of JAK2/STAT3 signaling. Here we show that
STAT3 phosphorylation also occurs rapidly in response
to an MFC-induced small molecule-protein interaction
in MASPIT, providing an assay format that might be
Chemistry & Biology
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(A) Rapid induction of STAT3 phosphorylation in MASPIT. HEK293T cells were transiently transfected with vector encoding EpoR-LepRF3-
DHFR and a vector encoding gp130-FKBP12F36V (top), gp130-CDK2 (middle), or gp130-GSK3b (bottom), and exposed to the indicated
MFC (1 mM each) in the presence or absence of Epo for 15 min. The percentage of p-STAT3-positive cells was then determined by flow
cytometry.
(B and C) MASPIT competition assays using the p-STAT3 readout. Cells were transiently transfected with EpoR-LepRF3-DHFR vector and the
indicated gp130-target vector. (B) Top: dose-dependent induction of STAT3 phosphorylation with MFC RGB-286580 (15 min exposure in the
presence of Epo). Bottom: competition assay (MFC, RGB-286580 at 1 mM) with the small molecule CDK inhibitor RGB-286147 (15 min expo-
sure time).
(C) Competition assay (MFC, RGB-286298 at 1 mM) with the GSK3b inhibitor RGB-285978 (15 min exposure time).
(D) Compound inhibition of HEK293T cell proliferation, as determined with the SRB assay (similar results were obtained with a viability assay;
data not shown). Induction of STAT3 phosphorylation or induction of the STAT3-responsive IL5R reporter was determined after 15 min or 16 hr
exposure, respectively, to LIF in the presence or absence of the indicated compounds at a concentration of 100 nM for RGB-285978 or RGB-
286147, or 1 mM for the indicated MFCs (all other compounds).
(E) RGB-285978 inhibits MASPIT signaling (target: GAK) but not MAPPIT signaling (SKP1/F box protein-protein interaction). Here we used
HEK293 cells stably expressing the EpoR-LepRF3-DHFR bait and the gp130-GAK prey (left half of gel for MASPIT experiment) or HEK293 cells
stably expressing EpoR-LepRF3-SKP1 and gp130-F box fusion proteins (right half of gel for MAPPIT experiment). F box is a protein of
unknown function that we identified in a MAPPIT cDNA library screen with SKP1 (data not shown). Two experimental setups were used:
(1) RGB-285978 competitor was added subsequent to incubation of cells with MFC (columns marked with +a; cells were incubated for
30 min with MFC, followed by addition of RGB-285978 for 30 min, followed by addition of Epo for 60 min); (2) all reagents were added simul-
taneously and cells were incubated for 60 min (columns marked +b). The same order of addition of compounds had no effect on Epo-
stimulated STAT3 phosphorylation in the SKP1/F box MAPPIT setting. pSTAT3 and STAT3 levels were determined by immunoblotting with
antibodies specific for these proteins.preferred over the transcription-based readout assay for
use with competitive compounds.
Accordingly, Figure 7A shows that a pronounced
Epo-dependent induction of STAT3 phosphorylation is
observed in transiently transfected HEK293T cells in re-
sponse to a 15 min exposure to an MFC, as shown for
RGB-286617 (target: FKBP12F36V), RGB-286580 (target:
CDK2), and RGB-286298 (target: GSK3b). Induction of
STAT3 phosphorylation was generally comparable in
magnitude to that observed for untransfected cells inresponse to LIF. As shown for RGB-286580, induction
of STAT3 phosphorylation was dose-dependent (Fig-
ure 7B). Figures 7B and 7C show results of competition
experiments with the kinase inhibitors RGB-286147 (tar-
get: CDK2) and RGB-285978 (target: GSK3b). For RGB-
286147, an EC50 (12 nM) comparable to the IC50 (15 nM)
for in vitro CDK2 inhibition was determined (Figure 7B).
For the GSK3b inhibitor RGB-285978, an EC50 (33 nM)
comparable to the IC50 (11 nM) for inhibition of GSK3b
kinase activity in vitro was obtained (Figure 7C). Neither
Mammalian Three-Hybrid System
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phosphorylation (Figure 7D), suggesting that these com-
pounds directly inhibited the respective MFC-target
interactions. Furthermore, as previously shown to be
the case for imatinib and its target ABL (Figure 6), these
results also suggest that these compounds target their
receptors in cells with high efficiency (at least when
these are expressed as gp130 fusion proteins).
In contrast to their lack of inhibition of LIF-induced
STAT3 phosphorylation upon short-term exposure
(100 nM, 15 min), RGB-286147 and RGB-285978 abro-
gated LIF-induced expression of the STAT3-responsive
IL5R reporter gene in HEK293 cells upon longer term
exposure (100 nM, 16 hr), as shown in Figure 7D. The
cause of these inhibitory effects could be their cytotoxic
activities and/or inhibition of STAT3-mediated transcrip-
tion. Both RGB-286147 and RGB-285978 are potent
cytotoxic agents against many different cell types ([15];
data not shown), including HEK293T cells (Figure 7D).
Although the potent antiproliferative/cytotoxic effects
of these compounds were apparent only by 48 hr
(Figure 7D), microscopic analysis revealed that by
24 hr, cells began to round up and to display significant
changes in morphology (data not shown), suggesting
that adverse effects on the viability of these cells might
have initiated at earlier time points. Alternatively, inhibi-
tion of LIF-induced IL5R expression could have involved
transcriptional effects, as both of these compounds are
potent inhibitors of cyclin-dependent kinases that are
known to be involved in gene transcription/elongation
(e.g., CDK7 and CDK9; [13, 15], and data not shown).
Thus, RGB-286147 and RGB-285978 are good exam-
ples of compounds for which a MASPIT STAT3 phos-
phorylation assay but not a MASPIT STAT3-dependent
reporter transcription assay would be suitable for com-
petition experiments and determination of EC50 values.
As shown in Figure 7D, none of the MFCs used in this
study inhibited LIF-induced IL5R expression, nor did
they exhibit adverse effects on cell proliferation and
viability (Figure 2)—which is consistent with the obser-
vations that these MFCs produced robust MASPIT sig-
nals. Interestingly, these observations were also made
for the MFCs of RGB-286147 and RGB-285978, com-
pounds which did inhibit LIF-induced IL5R expression
and displayed cytotoxic activities. It is conceivable
that modification of these compounds (linker addition
and coupling to MTX) resulted in the loss of specific in-
teractions mediating cytotoxic activities of these com-
pounds. Alternatively, it is also conceivable that such
modifications, in particular coupling with MTX (which re-
sults in a significantly bulkier molecule), simply reduces
the affinity of a small molecule for a target protein but not
its overall interaction fingerprint—and that interactions
of reduced affinity are still detectable with MASPIT.
For instance, with respect to RGB-286147 and the re-
spective MFC RGB-286156, we favor the latter scenario.
In this case, as shown previously [15], addition of the
PEG linker does not significantly influence the biological
potency of this pyrazolopyrimidone. However, subse-
quent coupling to MTX does reduce its in vitro kinase in-
hibitory potency (e.g., IC50 for CDK2/cyclinE was found
to be w200 nM for RGB-286156, compared to an IC50
of w15 nM for RGB-286147). Despite this effect, inter-
action with CDK2 can easily be detected with Y3H andMASPIT. Furthermore, as previously shown [15], RGB-
286156 interacts in Y3H with all the CDK/CRK kinases
that RGB-286147 and related analogs interact with
in vitro (with the exception of CDK7, which is likely to
require a trimeric enzyme complex not replicated in
yeast cells). Thus, although chemical modification might
affect the biological potency of a compound, it may not
necessarily change its target profile.
Screening for Interaction Modifiers Using Stably
Integrated MASPIT System Components
The experiments described above employed HEK293T
cells that were transiently transfected with expression
vectors encoding specific fusion proteins. Here we
show that HEK293 cells stably expressing EpoR-
LepRF3-DHFR and gp130 fusion proteins (such as those
identified in a cDNA library screen) can also be used to
perform competition experiments with a STAT3 phos-
phorylation assay. In this study, we did not use flow
cytometric detection of pY-STAT3-positive cells, but
an immunoblot assay for quantitation of relative cellular
levels of pY-STAT3 as compared to total cellular STAT3
levels. As outlined in Figure 7E, RGB-286298 induced
STAT3 phosphorylation in an Epo-dependent fashion as
a result of its interaction with a gp130-GAK target pro-
tein (we identified GAK as a novel kinase target of this
compound in a MASPIT cDNA library screen similar to
that described in Figure 4B). No induction of STAT3
phosphorylation was observed in the presence of the
competitor compound RGB-285978. Interestingly, RGB-
285978 repressed STAT3 phosphorylation irrespective
of whether it was added simultaneously with the MFC
and Epo (lanes marked with +b) or subsequent to pre-
incubation of cells with the MFC alone (30 min; lanes
marked with +a), that is, conditions in which an MFC-tar-
get complex would be allowed to form prior to addition of
competitor compound and subsequent stimulation with
Epo. These different experimental setups could be used
to determine whether a competitor compound would be
able to interfere with the formation of and/or disrupt
a small molecule-protein interaction. The inhibition of
STAT3 phosphorylation by RGB-285978 under both
experimental setups was specific, as indicated by the
lack of effect of RGB-285978 (even at high concentration,
400 nM) on the Epo-induced STAT3 phosphorylation in
the context of a MAPPIT protein-protein interaction
(SKP1/F box: the F box protein was identified as a novel
target protein in a MAPPIT cDNA library screen with
SKP1 as a bait; data not shown). We have previously
shown that RGB-285978 also does not inhibit LIF-
induced STAT3 phosphorylation (Figure 7D). Collec-
tively, these results show that a STAT3 phosphorylation
assay may be used with both MASPIT and MAPPIT to
rapidly screen for modifiers of small molecule-protein
or protein-protein interactions, respectively.
Discussion
Chemical dimerizers have been widely used to tempo-
rally control the dimerization of specific proteins and
the activity of signaling pathways in intact cells [36,
37]. Y3H extended the scope of chemical dimerizers to
proteome-wide identification of small molecule targets
[3, 12, 13, 15]. The MASPIT system described here
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dimerizers. It provides a complementary method to
Y3H for proteome cDNA library screening and target
identification. In addition, MASPIT provides an assay
platform for determining specificity and potency with
which unmodified small molecules interact with target
proteins in intact cells, and a new approach to compare
and contrast biological activity profiles of compounds of
various chemotypes and modes of action.
The multiple counterscreening options and quality
control measures that can be exercised in the monitor-
ing of MASPIT signaling events ought to contribute to
a high level of confidence with which small molecule-
protein interactions can be identified and characterized.
An example of this is the cDNA library screen for the ABL
kinase inhibitor PD173955, in which only kinases were
identified, all of which could be independently con-
firmed (we have made similar observations for other
compounds, including compounds that are not kinase
inhibitors; M.C. and N.K., unpublished observations).
The PD173955 interaction results also suggest that the
pyrido[2,3-d]pyrimidine kinase inhibitor scaffold consti-
tutes a core structure with potential for the rational
design of ephrin receptor tyrosine kinase inhibitors. Var-
ious members of this kinase subfamily have been impli-
cated in the regulation of numerous biological pro-
cesses, including disease pathogenesis (e.g., cancer).
By enabling the characterization of targeting poten-
cies, and thereby also a ranking of compounds based
on both qualitative as well as quantitative differences
in their target interaction fingerprints, MASPIT further
expands the scope of compounds that can be studied
with a 3H system. An important difference between
determination of EC50 values using MASPIT and in vitro
KD or IC50 determinations is that EC50 values also reflect
variables associated with compound bioavailability and
intracellular targeting efficacy, such as: (1) compound
uptake, compartmentalization, and stability; (2) the
effect that binding of compound to other cellular targets
might have on its interaction with the ‘‘intended’’ target;
(3) effects of certain intracellular molecules on target
binding (e.g., ATP, which is present at high concentra-
tions in cells, competes with kinase inhibitors for binding
to the active site of the enzyme [38]); and (4) effects that
posttranslational modifications of the target, or its asso-
ciation with other proteins, might have on compound
binding. Similar factors can result in shifts in IC50 values
(in vitro versus cellular), as observed when comparing in
vitro enzyme inhibition values with data on inhibition of
enzyme-catalyzed substrate modification in intact cells
(see PD173955 and imatinib examples in this study).
One caveat with the interpretation of MASPIT EC50
values is that they reflect the targeting efficacy of a com-
pound for a fusion protein (gp130 fusion). This is also the
case with other assays, such as in vitro enzyme assays
or phage display, which largely make use of recombi-
nant fusion proteins. However, it appears that in many
instances the intrinsic affinity of a small molecule for a re-
combinant versus nonrecombinant target protein is sim-
ilar. Notwithstanding this potential caveat, the results of
our study suggest that MASPIT EC50 values can be good
indicators of the relative efficacies with which one or
more compounds target a specific protein or subset of
proteins in intact cells, thereby providing a more directlink to phenotypic data. The STAT3 phosphorylation
assay would also enable the analysis of compounds with
cytotoxic activities, which could be important for the
analysis of certain anticancer agents. Thus, by enabling
a quantitative rather than strictly qualitative mapping of
small molecule-protein interaction fingerprints, MASPIT
could facilitate the tracing of a therapeutic or biological
effect of a compound to one or more of its molecular
targets, thereby also facilitating strategies for the opti-
mization of a compound for activity against a rationally
selected subset of targets. Quantitative target finger-
printing might also prove useful in the recognition of
potential new therapeutic applications of a small mole-
cule or chemical class.
As shown in this study, MASPIT signaling events can
readily be assessed by monitoring changes in the state
of STAT3 phosphorylation, irrespective of whether
MASPIT system components are expressed transiently
or constitutively (from stably integrated transgenes).
Transient expression studies are useful for performing
competition experiments without the need for selecting
stable integrants. In contrast, cells with integrated trans-
genes ought to be more appropriate if a larger number of
compounds are to be screened for interaction modifier
activity. The screening approaches described here
would support limited throughput screening of com-
pounds that interfere with or disrupt specific MFC small
molecule-protein interactions. This would be a typical
scenario for many lead optimization efforts. A high-
throughput STAT3 phosphorylation assay, for instance
a pY-STAT3 cytoblot assay [35], would further increase
the utility of MASPIT in larger scale compound-screen-
ing campaigns. A high-throughput pY-STAT3 assay
should similarly expand the range of applications of
MAPPIT or reverse-MAPPIT in screening for protein-
protein interaction modifiers. In summary, our study sug-
gests that MASPIT has potential for broad applications
in chemical biological research and drug discovery.
Significance
In this study we have described the development and
applications of MASPIT, a three-hybrid system for
small molecule-protein interaction profiling in mam-
malian cells. Our results show that MASPIT can be
used with a variety of small molecule chemotypes
and target classes, that it can be used in random pro-
teome screens for the de novo identification of small
molecule protein targets, and that it can be used to
determine the targeting potencies of small molecules
for specific targets in intact cells. The MASPIT system
should prove useful in (1) characterizing the target
spectra and selectivity profiles of small molecules,
(2) mechanism of action studies attempting to link
cellular targets to therapeutic/phenotypic effects of
small molecules, and (3) uncovering potential novel
therapeutic applications of drugs or drug candidates.
Experimental Procedures
MFC Synthesis
The chemical synthesis of the MFCs RGB-286156 and RGB-286580
has been described previously [13, 15]. The same strategy was used
for synthesis of other MFCs.
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HEK293T cells and the HEK293 reporter cell line, T-Rex44-eDHFR
[22], were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS). Cellular pro-
liferation was determined with the sulforhodamine B, SRB, assay
[39]. Cellular viability was determined with the CellTiterGlo lumines-
cent cell viability assay according to the manufacturer’s specifica-
tions (Promega).
Bait and Prey Constructs
The pSEL1 and pMG1 vectors for the transient expression of EpoR-
LepRF3 and gp130 fusion proteins, respectively, have been previ-
ously described [18]. The pCel1f vector, based on the cDNA5/FRT
vector, and used for directed integrated expression, has also been
described [20]. The bait plasmid pSEL-eDHFR was generated by
cloning the E. coli DHFR gene into pSEL using pBYK-DHFR [13] as
a template. pCel1f-eDHFR was constructed by ligating eDHFR to
the SacI and NotI sites of pCel1f. The CDK2, GSK3b, FKBP12F36V,
and carbonic anhydrase II (CAII) target plasmids were generated
by subcloning the coding regions of these genes into pMG1. The
ABL target construct was generated by cloning the kinase domain
of ABLl (amino acids 246–532). See Appendix 2 (in the Supplemental
Data available with this article online) for details of cloning. All
primers used in this study are listed in Appendix 1.
Construction of Cell Lines
The T-Rex44-eDHFR cell line was created from T-Rex44 by recom-
bining pCel1f-eDHFR into the FRT site. T-Rex44 has been previously
described [18, 22]. Integration of the expression cassette using the
flp-in system was done according to the manufacturer (Invitrogen).
T-Rex44-eDHFR-ABL was created from T-Rex44-eDHFR. Ecotropic
virus was prepared from pBG1-ABL and used to infect T-Rex44-
eDHFR at a one-half dilution. The rate of infection was presumed
to be 25% based on parallel infections with control vectors.
Transfections and MASPIT Reporter Assays/Competitions
HEK293T cells were grown to about 60% confluency in DMEM 10%
FCS and transfected with 100 ng of each plasmid of the standard
components (constructs carrying the EpoR-LepRF3-DHFR bait,
the rPAP1-luciferase reporter, and the b-galactosidase control vec-
tors) as well as the indicated gp130-target vector with TransIT-293
(Mirus, MIR2700). For induction of the MASPIT system, transfected
cells were cultured in fresh media containing recombinant human
erythropoetin (Epo) (5 units/ml of culture media; R&D Systems,
287-TC) in the presence of MFC for an additional 24 hr. In the stan-
dard competition assay, the MASPIT system was induced by the
simultaneous exposure of transfected cells to Epo, the MFC, and
the competitor compound for 24 hr. Cell lysates were prepared
and b-galactosidase normalized luciferase activity was determined
(Promega, E1501 and E2000). Variation in the MASPIT signal be-
tween wells transfected with the identical plasmid/lipid mixture
was routinely found to be less than 10%. For reporter induction with
leukemia inhibitory factor (LIF; Chemicon International, Lif1010),
cells were treated with 1 ng/ml cytokine for 15 min (STAT3-Y705
detection) or 16 hr (IL5R detection).
Enzymatic Assays
CAII assays were performed at CEREP (Paris). CDK2 kinase assays
were done as previously described [28]. All other kinase assays were
performed at Upstate (Dundee, UK).
Western Blot Analysis
Western blot analysis was performed using standard procedures;
see Appendix 2 for experimental details. The gp130-CDK2 fusion
protein was detected with an anti-gp130 rabbit polyclonal antibody
(Upstate). STAT3 was detected with a mouse anti-phospho-
STAT3(Y705) antibody (Upstate) and a rabbit anti-STAT3 antibody
(Santa Cruz Biotechnology).
Flow Cytometric Detection of p-STAT3 and p-CrkL
HEK293T cells were fixed and permeabilized for staining with
the PE-conjugated anti-phospho-STAT3 (Y705) antibody (BD Bio-
sciences, 612569). KU-812 cells were fixed and permeabilized for
staining with an anti-p-CrkL antibody (Cell Signaling, 3181) andFITC-labeled secondary antibody (BD Biosciences, 554020). The
stained cells were analyzed on a BD FACS Canto flow cytometer.
See Appendix 2 for details.
cDNA Library Construction
Construction of the HEK293T cDNA library was done using stan-
dard procedures with random and oligo dT-primed cDNAs syn-
thesized using the Superscript Choice system (Invitrogen). The
library vector, pLN-CD90-CMV-gp130-ccdB, was constructed from
pLNCX2 (Clontech). See Appendix 2 for details.
cDNA Library Screen and IL5R Staining
T-Rex44-eDHFR cells (4.43 108 cells) were infected with a retroviral
cDNA library at a rate of 25% (infection efficiency). After 24 hr, the
media was replaced with fresh media and the cells were allowed
to recover for an additional 24 hr. Cells were stimulated with RGB-
286649 (150 nM) and Epo (3 U/ml) for 24 hr and then stained for
expression of the IL5R. The a-IL5R antibody (hybridoma 16-4 [22])
was used at 1.0mg/ml. The secondary antibody was a PE-conjugated
goat a-mouse IgG1 (Molecular Probes; used at 1.5 mg/ml). IL5R-
positive cells were then either quantified by FACS or enriched on
a-PE magnetic beads (500 ml) (StemCell Technologies). In the cDNA
library screen, the IL5R-positive cells were enriched on five LS col-
umns (Miltenyi). The cells were eluted through removal of the mag-
netic field and were allowed to recover. To deplete background
due to constitutive activation of the IL5R reporter, cells were stained
for expression of IL5R in the presence of Epo but absence of RGB-
286649 and then reapplied to an LS column. The flow through was
collected and the cells were allowed to recover. The recovered cells
were stimulated with Epo and RGB-286649 and individual IL5R-
positive cells were seeded into 96-well plates using a flow cytometer.
Alternatively, IL5R-positive cells were enriched an additional time
using a-PE magnetic beads, allowed to recover, and then seeded
into 96-well plates using a flow cytometer. The cell lines that grew
from the 96-well plate were retested for Epo- and RGB-286649-
dependent IL5R expression by flow cytometry. Alternatively, immu-
nological detection of the IL5R can be performed with a dot blot
assay. The cDNA harbored in these cells was isolated by RT-PCR.
RNA was isolated using an RNAeasy kit (Qiagen) and RT-PCR was
performed using a One Step RT-PCR kit (Qiagen) with primers
gp130F and 30LNCX2-R1.
Supplemental Data
Supplemental Data contain experimental procedures, including
oligonucleotide sequences and antibodies, and are provided in
Appendices 1 and 2, which can be found with this article online
at http://www.chembiol.com/cgi/content/full/13/7/711/DC1/.
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